technology

press releases

Date Title and Summary Additional Formats
Toggle Summary BOTHELL, Wash. , Feb. 19, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its fourth quarter and year-end 2017 financial and View HTML
Toggle Summary BOTHELL, Wash. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today that the underwriters of its previously announced offering of 2.50% View HTML
Toggle Summary BOTHELL, Wash. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Randall C. View HTML
Toggle Summary Augments $100 million in gross proceeds received in the $250 million January 2018 committed equity financing with Redmile Group, LLC investors; remaining $150 million undrawn capacity terminated BOTHELL, Wash. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. View HTML
Toggle Summary BOTHELL, Wash. , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today an underwritten offering of $250 million aggregate principal amount of 2.50% View HTML
Toggle Summary BOTHELL, Wash. , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today an underwritten offering of $200 million aggregate principal amount of View HTML
Toggle Summary BOTHELL, Wash. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it has entered into a definitive preferred stock purchase agreement View HTML
Toggle Summary BOTHELL, Wash. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it has entered into a European patent settlement and global license View HTML
Toggle Summary -- Highly statistically significant results with rapid prevention beginning Day One,  50%, 75%, 100% responder rates by month one sustained for three months -- -- 15% of patients had no migraines for a full three months -- -- Conference call and webcast to be held today, January 8 , at 8:30 a.m. View HTML
Toggle Summary BOTHELL, Wash. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast its presentation at the upcoming J.P. View HTML